Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid CardiomyopathyPerry Elliott, Sanjiv J. Shah, Brian Drachman et al.|Circulation Heart Failure|2021Cited by 198
1169Interim analysis of data from a long-term, extension trial of tafamidis meglumine in patients with transthyretin amyloid cardiomyopathyPerry Elliott, Sanjiv J. Shah, Brian Drachman et al.|European Heart Journal|2019Cited by 7
Long-term Survival in People With Transthyretin Amyloid Cardiomyopathy Who Took Tafamidis: A Plain Language SummaryPerry Elliott, Sanjiv J. Shah, Brian Drachman et al.|Future Cardiology|2023Cited by 3
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers populationMaría G. Crespo‐Leiro, Brian Drachman, Michael G. Hanna et al.|European Heart Journal|2024Cited by 0
Early Access to Tafamidis for Patients With Transthyretin Amyloid CardiomyopathyMaría G. Crespo‐Leiro, Brian Drachman, Mazen Hanna et al.|JACC Advances|2025Cited by 0